The developments at Holland Capital in 2024 reflect our strong ambitions
Amsterdam/ Düsseldorf, 30th of December 2024 –The developments at Holland Capital in 2024 reflect our strong ambitions. Guided by a focused investment strategy, we continued to actively engage in the high-growth markets of Technology, Healthcare, and Agrifood. Reflecting on a successful year, we completed several key transactions and further strengthened our team.
2024 achievements
- The launch of our fund, Holland Capital Growth and Buy-Out Fund V
- Number of deals in the Netherlands: 5
- Number of add-on acquisitions in the Netherlands: 13
- Number of add-on acquisitions in Germany: 2
- Number of exits: 2
- Number of new colleagues: 4
Sector focus and an entrepreneurial hands-on approach: With specialized sector teams, we focus on the sectors of Healthcare, Technology, and Agrifood, both within the Growth & Buy-out and Venture & Growth segments. We understand the dynamics and opportunities in these sectors and have an extensive network. Holland Capital is not a passive investor; we work closely with management to define and execute strategies. Where needed, our operational team also contributes hands-on to the realization of specific projects within the company.
Which companies would we like to connect with?
- Sector: Technology, Healthcare, and Agrifood
- Positive outlook: Significant growth potential, both autonomous and buy-and-build
- Growth & Buy-out:
- Healthy profitability: cash flow from operations (EBITDA) between EUR 1 – 10m
- Smaller companies: considered as add-on acquisitions for our existing portfolio companies
- Larger companies: considered together with a co-investor
- Venture & Growth:
- Start-ups and scale-ups: EBITDA EUR <1m
- Cash flow negative (in an accelerated growth scenario)
- Revenue EUR 0 – 5m
What to expect from us?
- Flexible approach to transaction structures: We strive to adapt each structure to the needs of the company and its shareholders. Depending on the type of investment, Holland Capital either provides growth capital and/or acquires existing shares. We are flexible regarding the final capital structure: both majority and minority stakes are possible.
- Deal certainty and an efficient process: Thanks to our sector expertise, we are able to quickly assess a business model and put a fair price on the table. Since the partnership with the entrepreneur and/or the management team is the cornerstone of our investment, we devote above-average attention to ensuring the process is completed efficiently, in the right spirit, and with mutual respect for both parties.
- Transparency towards advisors: We appreciate it when advisors involve us early in discussions with entrepreneurs and/or management teams. In such cases, we always ensure that the advisor’s interests are well safeguarded throughout the process. The advisor retains the flexibility to decide whether to represent the sell-side or buy-side in a potential transaction.
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and fosters an open, sustainable, and professional relationship with the management teams of the invested companies, aiming for mutual growth. With offices in Amsterdam and Düsseldorf, Holland Capital focuses on Healthcare, Technology, and Agrifood-Tech sector.
Roelant Prins (Adyen) deelt zijn ervaringen tijdens Eerste Holland Venture Growth Session
De eerste Holland Venture Growth Session, met Roelant Prins - CCO van Adyen - als gastspreker, was een groot succes. In een interactieve sessie deelde Roelant zijn ervaringen met het aansturen van een snelgroeiende organisatie en het opzetten van buitenlandse...
Roelant Prins (Adyen) shares his experiences at Holland Venture’s first Growth Session
Holland Venture’s first Growth Session, with guest speaker Roelant Prins – CCO of Adyen – was a great success. In an interactive session with entrepreneurs and the Holland Venture team participating, Roelant shared his experiences in managing a fast growing...
Succesvolle financieringsronde voor innovatief beademingsapparaat van Ventinova
Eindhoven, 26 november 2015 – Ventinova Group B.V. heeft een succesvolle tweede financieringsronde afgerond met haar bestaande aandeelhouders Holland Venture en de Brabantse Ontwikkelings Maatschappij (BOM). Daarnaast is een nieuwe aandeelhouder toegetreden,...
Holland Venture realiseert uitstekend resultaat door verkoop Bureau PENG
Amsterdam 6 oktober 2015 - Vorig week heeft Holland Venture de overnamecontracten getekend waarmee zij haar aandelen in Bureau PENG heeft verkocht aan de huidige directeur Martijn van Kraaij en een Nederlandse family office. Bureau PENG biedt flexibele personele...
Substantiële EU subsidie voor revolutionaire levensreddende beademingsmethode
Eindhoven 24 september 2015 - Ventinova Medical B.V., een bedrijf dat innovatieve medische producten ontwikkelt en verkoopt op het gebied van anesthesiologie heeft samen met drie partners een EU subsidie ontvangen van EUR 1,9 miljoen. Als derde geselecteerd van de 269...
Holland Venture start technologie fonds
Amsterdam, 20 augustus 2015 - Holland Venture heeft een nieuw fonds opgezet voor jonge, snelgroeiende technologie bedrijven. Het Holland Venture Technologie Fonds richt zich op zes specifieke aandachtsgebieden: mobiel internet, software in de cloud,...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl